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Background: Despite improvement in hepatitis B infection prevention through nation-
al vaccination programs, implementation of compulsory and thorough blood donor 
screening, and reduction of transfusion numbers due to erythropoietin administration, 
hepatitis B remains a major concern in hemodialysis (HD) centers (1). Compared to a 
response rate of over 90% in the normal population, only 50 to 60% of those with end-
stage renal disease (ESRD) achieve protective antibody levels following immunization 
against hepatitis B (2, 3). Various strategies have been developed to overcome the low se-
roconversion rate in ESRD patients, including co-administering zinc, gamma-interferon, 
thymopentin, interleukin-2, and levamisole as immunostimulants or adjuvants (3, 4), 
changing the injection mode (intradermal versus intramuscular), or doubling the vac-
cine dose (5). 
Objectives: Previous studies demonstrated that renal failure patients beneﬁt from HBV 
vaccination; however, not all studies have demonstrated this. Therefore, we compared 
the rates of seroconversion (hepatitis B surface antibody [HBsAb] titer > 10 IU/mL) in pa-
tients at various stages of chronic kidney disease (CKD) (estimated glomerular ﬁltration 
rate [eGFR] < 60 mL/min/1.73 m2) who received HBV vaccination.
Patients and Methods: A total of 167 patients in 3 diﬀerent stages of CKD were vaccinated 
against HBV. Each patient received the vaccine according to a standardized vaccination 
schedule consisting of 40 μg of the recombinant vaccine “Engerix” at 0, 1, and 6 months. 
Eight to 12 weeks after the last dose of vaccination, anti-HBsAb levels were measured. 
Results: Mean age and eGFR were 57.4 ± 16.5 years and 26.7 ± 14.7 mL/min/1.73 m2, re-
spectively. The overall seroconversion rate was 78%. Although a signiﬁcant correlation 
between HBsAb titer and eGFR (r = 0.265, P = 0.001) was observed, in the multivariate 
analysis using age, CKD stage, diabetes mellitus, and gender as independent variables, 
the degree of renal function did not signiﬁcantly contribute to seroconversion. In con-
trast, higher age (> 60 years) showed a signiﬁcant negative correlation to seroconver-
sion (odds ratio = 0.22; P = 0.004).
Conclousions: CKD patients of advanced age should be vaccinated against HBV. Although 
higher eGFR was not associated with improved seroconversion, the persistence of sero-
conversion was not evaluated; future studies should be conducted to develop recom-
mendations for earlier or later vaccination.
 Implication for health policy/practice/research/medical education:
Old CKD patients should have HBV Vaccination as soon as possible which may not be true for younger ones.
  c 2011 Kowsar M.P.Co. All rights reserved.
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1. Background
Hepatitis B virus (HBV) infection is a widespread but 
preventable disease. The prevalence of HBV in hemodi-
alysis (HD) patients varies signiﬁcantly between coun-
tries, ranging from very low in developed countries to 
very high in some developing countries. HD patients are 
susceptible to infection with HBV and hepatitis C virus 
(HCV) resulting from blood transfusion, frequent injec-
tions, partial immunosuppression, or history of trans-
plantation. Despite improvements in the prevention of 
HBV infection through national vaccination programs, 
implementation of compulsory and thorough blood 
donor screening, and reduction of transfusion numbers 
due to erythropoietin administration, HBV infection re-
mains a major concern in HD centers (1). Compared to a 
response rate of over 90% in the normal population, only 
50 to 60% of those with end-stage renal disease (ESRD) 
achieve protective antibody levels following immuniza-
tion against HBV (2, 3). Various strategies have been uti-
lized to overcome the low seroconversion rate in ESRD 
patients, including co-administering zinc, gamma-inter-
feron, thymopentin , interleukin-2, and levamisole as im-
munostimulants or adjuvants (3, 4) as well as changing 
the injection mode (intradermal versus intramuscular) 
or doubling the vaccine dose (5). 
2. Objectives
Because immune system abnormalities correlate with 
the degree of renal failure, patients with CKD who do not 
require dialysis may have a stronger immune system and 
higher antibody response rate to HBV vaccination than 
patients who are on renal replacement therapy (6). Early 
studies demonstrated that renal failure patients beneﬁt 
from vaccination; however, not all studies have consis-
tently shown this beneﬁt (7). Therefore, we designed this 
study to compare the response rates of patients at diﬀer-
ent stages of CKD to HBV vaccination.
3. Patients and Methods
Between October 2007 to 2009, 134 cases of CKD (esti-
mated glomerular ﬁltration rate [eGFR] < 60 mL/min/1.73 
m2) with evidence of a high creatinine level and chronic-
ity as determined using clinical history or ultrasound 
ﬁndings with negative test results for hepatitis B surface 
antigen (HBsAg), anti-hepatitis core antibody (anti-HB-
cAb), anti-hepatitis B surface antibody (anti-HBsAb), and 
HCV antibody were included in the study. The partici-
pants were identiﬁed in 2 renal outpatient clinics that 
oﬀer diagnostic and follow-up services for patients with 
renal disease. An additional 33 chronic HD patients (prev-
alent cases) with the described inclusion criteria were 
added to the group. A total of 167 patients were included 
in the cohort. Exclusion criteria were current use of im-
munosuppressive medications and prior history of HBV 
vaccination or liver disease according to history and liver 
function tests. Each patient received the vaccine accord-
ing to the standardized vaccination schedule, i.e. 40 μg of 
the recombinant vaccine “Engerix” (20 μg in each deltoid 
region) at 0, 1, and 6 months. Patients received vaccina-
tions through their community health centers or from 
family physicians, and documents of vaccination were 
reviewed at each medical visit. In addition to blood tests 
performed at regular intervals of 0, 2, and 6 months, de-
mographic data were collected from all patients. Labo-
ratory tests included serum creatinine, hemoglobin, 
electrolytes, albumin, calcium, and phosphate. Medica-
tions were also recorded at the start of the immuniza-
tion schedule and at regular visits. Eight to 12 weeks after 
receiving the last vaccination dose, the anti-HBsAb level 
was measured. An anti-HBsAb titer of > 10 IU/L was con-
sidered to be a marker of positive seroconversion.
Mean creatinine levels during the 3 visits were used to 
calculate the eGFR using the Modiﬁcation of Diet in Renal 
Disease (MDRD) formula. Subjects were categorized into 
3 subgroups according to their eGFR: 30–59 mL/min/1.73 
m2 (stage 3; 74 subjects), 15–29 mL/min/1.73 m2 (stage 4; 49 
subjects), and < 15 mL/min/1.73 m2 (stage 5; 42 subjects). 
Ten patients with stage 5 disease did not start dialysis 
therapy before the vaccination schedule was completed. 
3.1. Statistical Analysis:
Descriptive analyses were used to characterize the 
participant population. Continuous variables were 
compared by eGFR value using Pearson’s correlation co-
eﬃcient. Partial correlation was used to explore the re-
lationship between eGFR and HBsAb while controlling 
for age. Continuous and categorical variables were com-
pared by CKD stage as categorical variables using analy-
sis of variance and chi-square test, respectively. Analyses 
were conducted using the Statistical Package for the So-
cial Sciences, version 15.0 (SPSS Inc., Chicago, IL). We used 
the independent-samples t-test and Mann-Whitney U test 
to compare baseline characteristics between seroconver-
ters and non-seroconverters. A P < 0.05 was considered 
to indicate statistical signiﬁcance. A linear regression 
model was used to identify the factor with the greatest 
impact on seroconversion.
4. Results
A total of 167 CKD patients were vaccinated against HBV. 
Overall, 130 patients were seroconverted following HBV 
vaccination (seroconversion rate was 78%). Thirty three 
patients were on dialysis, but the remaining patients 
with stage 5 CKD did not start dialysis before complet-
ing the vaccination protocol. The demographic data of 818
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patients according to their CKD stage are listed in Table 
1. The mean age was 57.4 ± 16.5 years, the male-to-female 
ratio was 96/71, and the mean creatinine and eGFR lev-
els were 3.84 ± 3.41 mg/dL and 26.7 ± 14.7 mL/min/1.73 m2, 
respectively. Diﬀerences were observed in hemoglobin, 
albumin, and weight which were expected due to the 
impact of the decreased eGFR on these factors. When ad-
justed for age, there was a correlation between eGFR and 
HBsAb titer (r = 0.3037, P = 0.001), but the signiﬁcance 
of eGFR could not be demonstrated between respond-
ers and non-responders (P = 0.547) (Table 2). A weak but 
signiﬁcant correlation between HBsAb titer and eGFR (r 
= 0.265, P = 0.001) was observed between sexes (men: r 
= 0.291, P = 0.005; women: r = 0.04,5 P = 0.713), but this 
diﬀerence was not signiﬁcant (Zobs = 1.57). In a linear re-
gression model controlled for age, gender, creatinine, 
weight, cholesterol, and Hb. Level of HBV antibody after 
HBV vaccination did not reveal a statistically signiﬁcant 
diﬀerence across diﬀerent stages of CKD.
The HBV antibody titer was also treated as categorical 
variable. An HBV antibody titer above 10 IU/L was consid-
ered as cut-oﬀ point for seroconversion. In a multivariate 
logistic regression model, after adjusting for age, gender, 
creatinine, weight, and diabetes mellitus (as the cause of 
CKD), HBV seroconversion was not signiﬁcantly diﬀerent 
between the 3 stages of CKD. In addition, when serocon-
version was examined with regard to the eGFR levels us-
ing 10-mL/min categories (Figure 1), no signiﬁcant impact 
could be observed (P = 0.693).
Responders (n = 130) Non-responders (n = 37) P value
Sex 0.919
Male
Female
75
55
21
16
Age, y, mean ± SD 55.5 ± 16.4 64.5 ± 14.7 0.003
Age > 60 y, No. (%) 61 (46.9) 27 (73)
Diabetes a, % 22.4 12.9 0.143
Weight, kg 70.4 ± 12.5 70.1 ± 17.9 0.938
eGFR b, mL/min, mean ± SD 27.0 ± 15.1 25.36 ± 13.71 0.547
Hemoglobin, g/dL, mean ± SD 12.6 ± 2.0 12.0 ± 1.9 0.158
Cholesterol, mg/dL, mean ± SD 174.4 ± 37.4 196.4 ± 39.8 0.006
Table 2. Univariate Comparison and Kidney Function
a Cause of CKD
b GFR is calculated using the modiﬁcation of diet in renal disease (MDRD) formula.
GFR a, b, mL/min
30-59 (n = 75) 15-29  (n = 50) < 15 mL (n = 42) P value
No Dialysis (n = 9) On Dialysis (n = 33) Total
Sex
Male
Female
53
22
19
31
24
18
0.001
Age, y, mean ± SD 61.5 ± 14.7 59.7 ± 17.0 54.6 ± 16.4 45.0 ± 13.6 < 0.001
Age > 60 y 27/48 21/29 5/9 6/33 0.001
Cause of CKD a
Diabetes
Total
12
75
16
50
9
42
0.107
Weight, kg 73.5 ± 12.7 72.1 ± 15.7 60.7 ± 13.1 64 ± 12.0 < 0.001
Serum creatinine, mg/dL, mean ± SD 1.7 ± 0.3 2.8 ± 0.61 8.9 ± 3.4 < 0.001
GFR a, mL/min , mean ± SD 40.5 ± 6.8 22.2 ± 4.6 12.4 ± 1.6 5.9 ± 1.7 < 0.001
Hemoglobin, g/dL, mean ± SD 13.3 ± 1.9 11.7 ± 1.7 10.5 ± 1.5 < 0.001
HBsAb, mean ± SD 150.6 ± 187.6 115.5 ± 144.3 77.9 ± 81.9 84.4 ± 65.1 0.067
Positive HBs Ab response, No. (%) 60 (80) 38 (76) 6 (67) 26 (79) 0.067
Table 1. Patient Demographic Data According to Chronic Kidney Disease Stage
a Abbreviations: CKD, Chronic Kidney Disease; GFR, Glomerular Filtration Rate
b GFR is calculated using the modiﬁcation of diet in renal disease (MDRD) formula.819
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5. Discussion
For HBV patients examined in our hospital (age; mean: 
57.38 years, median: 60.00 years), the MDRD formula 
is considered to be the most appropriate method for 
determining eGFR. In a separate study involving more 
than 30,000 subjects, it was shown that more signiﬁcant 
underestimation occurred when using the corrected 
Cockcroft-Gault equation compared to the MDRD for-
mula in subjects older than 55 years, although a strong 
correlation was observed between the 2 methods (r = 
0.91, P = 0.001) (8). In our study, although the CKD stage 
weakly contributed to a higher HBsAb titer, it did not 
signiﬁcantly correlate with the seroconversion rate. This 
ﬁnding does not indicate that earlier vaccination is eﬃ-
cacious (9, 10). Although stage 5 CKD patients who were 
on HD at the time when we started vaccination were in-
cluded (32/42) in our study, a negative impact of a higher 
CKD stage on the seroconversion rate was not observed. 
Our results were similar to those of McNulty et al. who 
excluded patients on required dialysis (9), or DaRoza et 
al. who enrolled 14 of 49 patients with stage 5 CKD who 
required dialysis therapy before completing the vaccina-
tion series (6).
In contrast to the study by DaRoza et al. no statistically 
signiﬁcant diﬀerence in seroconversion was observed in 
diﬀerent 10-mL/min of GFR categories (P = 0.693) (Figure 
1). Because the mean eGFR in stage 3 CKD patients in our 
study was higher than that in DaRoza’s study (41 [30–55] 
vs. 37 [34–43] mL/min/1.73 m2), the present study is more 
reliable. Our results agree with those of McNulty, who 
recommended immunization of patients with progres-
sive kidney disease, preferably in the preterminal stage 
but not as soon as possible (9). Bel’eed et al. also found 
that seroconversion rates were similar in HD patients 
(66%; 90/136), peritoneal dialysis patients (66%; 36/55), 
and predialysis patients (68%; 13/19) (10).
Serocoversion rate in 30 CKD patients with similar vac-
cination schedule was studied by Siddiqui et al . They di-
vided the patients according to their creatinine level to 
mild CKD (2.5 ± 1.1mg/dL, range: 1-3); moderate CKD (4.6 
± 1.5 mg/dL, range: 3.1-6) and ESRD (8.4 mg/dL, range: > 
6) . They found seroprotection rate in three groups as 
100%,90.1% and 54.5% respectively. (11) However, it should 
be noted that according to the mean level of creatinine, 
it seems that moderate CKD in their study may be catego-
rized as stage 4 of CKD and even 5 and it may suﬀer from   
relative disparity in groups. As similar creatinine level in 
diﬀerent age and weight groups may indicate diﬀerent 
level of kidney function.
Age is an important contributing factor of responsive-
ness to HBV vaccination in ESRD patients as well as dur-
ing the pre-ESRD period (6, 9, 12-14). Jadoul et al. in a study 
involving HD patients, showed that seroconversion rates 
after 12 months were 100%, 75%, and 50% in patients aged 
< 60 years, 60–75 years, and > 75 years, respectively. Pa-
tients with seroconversion were younger (66 ± 14 years) 
than those without seroconversion (76 ± 9 years) (P = 
0.048) (15). In a meta-analysis of 17 clinical trials of hepa-
titis B vaccine in patients with ESRD, Fabrizi et al. showed 
a clear association between advanced age and impaired 
response to HBV vaccine in ESRD patients (RR: 0.74; P = 
0.0139) (13).
The success rate of anti-HBV immunization is markedly 
lower in HD patients (around 60%) than in non-uremics 
(over 90%). Interestingly, our study showed that patients 
with stage 3 CKD were older than those with stage 5 CKD, 
which is in contrast to some reports showing that older 
patients are typically referred to nephrologists at a later 
stage (16). Older patients seek medical advice for diﬀer-
ent health problems and are referred to nephrologists by 
other specialists. In addition, physician referrals in Iran 
are not limited according to laws of insurance agencies, 
which may be helpful for follow-up of patients. In conclu-
sion, vaccination at an earlier stage of CKD as compared 
to at a later stage did not result in a signiﬁcantly higher 
rate of seroconversion. However, the persistence of sero-
conversion was not evaluated in this study.
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